<code id='CBDAD61BCD'></code><style id='CBDAD61BCD'></style>
    • <acronym id='CBDAD61BCD'></acronym>
      <center id='CBDAD61BCD'><center id='CBDAD61BCD'><tfoot id='CBDAD61BCD'></tfoot></center><abbr id='CBDAD61BCD'><dir id='CBDAD61BCD'><tfoot id='CBDAD61BCD'></tfoot><noframes id='CBDAD61BCD'>

    • <optgroup id='CBDAD61BCD'><strike id='CBDAD61BCD'><sup id='CBDAD61BCD'></sup></strike><code id='CBDAD61BCD'></code></optgroup>
        1. <b id='CBDAD61BCD'><label id='CBDAD61BCD'><select id='CBDAD61BCD'><dt id='CBDAD61BCD'><span id='CBDAD61BCD'></span></dt></select></label></b><u id='CBDAD61BCD'></u>
          <i id='CBDAD61BCD'><strike id='CBDAD61BCD'><tt id='CBDAD61BCD'><pre id='CBDAD61BCD'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          explore

          author:entertainment    - browse:3
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP

          The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a new approach to treating ulcerative colitis, a chronic inflammatory disease that can cause intense gastrointestinal pain and distress.

          The therapy, dubbed Omvoh, is an antibody that blocks IL-23p19, an immune signaling molecule that plays a key role in sustaining the disease. It’s the first treatment to target this particular pathway in ulcerative colitis. The drug’s approval comes after two late-stage trials found that patients taking Omvoh showed a significant improvement in symptoms after both three months and a year compared with those given a placebo, and that the therapy had minimal side effects.

          advertisement

          Omvoh’s list price will be $9,593 per month for intravenous delivery and $10,360 per dose injected beneath the skin. A company spokesperson told STAT that patients who have the drug covered by commercial insurance may pay as little as $5 per month for up to 30 months.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge